Article Text

Download PDFPDF
Hepatocellular carcinoma: killing one bird with two stones
  1. Marina Ruiz de Galarreta,
  2. Amaia Lujambio
  1. Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York City, New York, USA
  1. Correspondence to Amaia Lujambio, Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA; amaia.lujambio{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hepatocellular carcinoma (HCC) is a very aggressive disease and represents the most frequent form of liver cancer. Although treatment of HCC has greatly improved over the last decade, most patients with HCC diagnosed at advanced stages are ineligible for curative ablative therapies such as liver resection or liver transplantation.1 Several multikinase inhibitors, including sorafenib, regorafenib, lenvatinib and cabozantinib, are approved by the Food and Drug Administration for the treatment of patients with advanced HCC, providing limited survival benefits.1 In the last 2 years, the programmed cell death receptor 1 (PD-1) immune checkpoint inhibitors (ICIs) nivolumab and pembrolizumab have also been approved for the treatment of patients with advanced HCC. While immunotherapies have aroused tremendous enthusiasm among clinicians and scientists,2 only a small percentage of patients respond with clinical benefit. One strategy to improve clinical outcomes would be to select those patients who are most likely to respond to ICIs by defining accurate and validated biomarkers of response. A second approach, which is somehow bolder, is to combine two drugs that synergise at killing the tumour cells. In fact, combination immunotherapies have proven effective in melanoma,3 where the first immunotherapy sensitises the tumour cells to the second one.

Activation …

View Full Text


  • Contributors MRdG and AL wrote the commentary.

  • Funding This study was funded by Fundación Alfonso Martín Escudero ( and grant number: Postdoctoral fellowship, National Cancer Institute ( and grant number: R37 Merit Award (R37CA230636), Damon Runyon Cancer Research Foundation ( and grant number: Innovator Award.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Patient consent for publication Not required.

Linked Articles